The global adeno-associated virus (AAV) vector-based gene therapy market is expected to witness significant growth during the forecast period of 2023-2031, driven by the rising prevalence of genetic disorders and the increasing investments in research and development activities. The market is projected to grow at a CAGR of 18.5% during the forecast period.
The AAV vector-based gene therapy market is expected to witness significant growth in the coming years due to the increasing prevalence of genetic disorders and the rising demand for innovative treatment options. The development of advanced technologies, such as genome editing and gene silencing, is expected to further drive the growth of the market. Additionally, the increasing focus on precision medicine and personalized treatment options is likely to create lucrative opportunities for the market players.
Furthermore, the increasing investments in research and development activities, coupled with the growing number of clinical trials, are expected to fuel the growth of the market. The adoption of advanced healthcare infrastructure and the increasing demand for better healthcare services in emerging economies are expected to further contribute to the growth of the market.
Adeno-Associated Virus Vector-Based Gene Therapy Market: Introduction
The global adeno-associated virus (AAV) vector-based gene therapy market report provides an in-depth analysis of the market and its segments. AAV is a non-pathogenic virus that is used as a delivery vehicle for therapeutic genes to treat genetic disorders. The report covers the market for AAV vector-based gene therapy and provides a detailed analysis of the market size, growth, and trends.The AAV vector-based gene therapy market is expected to witness significant growth in the coming years due to the increasing prevalence of genetic disorders and the rising demand for innovative treatment options. The development of advanced technologies, such as genome editing and gene silencing, is expected to further drive the growth of the market. Additionally, the increasing focus on precision medicine and personalized treatment options is likely to create lucrative opportunities for the market players.
Furthermore, the increasing investments in research and development activities, coupled with the growing number of clinical trials, are expected to fuel the growth of the market. The adoption of advanced healthcare infrastructure and the increasing demand for better healthcare services in emerging economies are expected to further contribute to the growth of the market.
Adeno-Associated Virus Vector-Based Gene Therapy Market Segmentations
The market can be categorised into therapeutic agents, indication type, and treatment channel.Market Breakup by Therapeutic Agents
- Corticosteroid Drugs
- Immunosuppressive Drugs
- ACE Inhibitors and ARBs
- Others
Market Breakup by Indication Type
Haematological Disorders
- Haemophilia A
- Haemophilia B
Ophthalmological Disorders
- Chloridaemia
- Retinitis Pigmentosa
Lysosomal Storage Disorders
- Fabry Disease
- Pompe Disease
- Hunter Syndrome
Neurological Disorders
- Parkinson's Disease
- Batten Disease
Musculoskeletal Disorders
- Duchenne Muscular Dystrophy (DMD)
- Spinal Muscular Atrophy (SMA)
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Adeno-Associated Virus Vector-Based Gene Therapy Market Scenario
The global adeno -Associated Virus (AAV) vector-based gene therapy market is expected to witness significant growth during the forecast period of 2023-2031. North America dominates the market, followed by Europe and Asia Pacific. The high prevalence of genetic disorders in North America, coupled with the favorable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for AAV vector-based gene therapy, with the presence of key players and increasing investments in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of genetic disorders and rising healthcare expenditure in the region.Key Players in the Global Adeno-Associated Virus Vector-Based Gene Therapy Market
The report gives an in-depth analysis of the key players involved in the adeno-associated virus vector-based gene therapy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:- Arya Sciences Acquisition Corp
- Pfizer Inc
- Roche Holding AG
- BioMarin Pharmaceutical Inc
- Bayer AG
- Coave Therapeutics
- MeiraGTx Limited
- Neurocrine Biosciences, Inc
- Biogen, Inc
- Sangamo Therapeutics
- Sarepta Therapeutics, Inc
Table of Contents
1 Preface
4 Adeno-Associated Virus Vector-Based Gene Therapy Overview
5 Patient Profile
6 Current Scenario Evaluation and Regulatory Framework
7 Challenges and Unmet Needs
8 Global Adeno-Associated Virus Vector-Based Gene Therapy Market
9 North America Adeno-Associated Virus Vector-Based Gene Therapy Market
10 Europe Adeno-Associated Virus Vector-Based Gene Therapy Market
11 Asia Pacific Adeno-Associated Virus Vector-Based Gene Therapy Market
12 Latin America Adeno-Associated Virus Vector-Based Gene Therapy Market
13 Middle East and Africa Adeno-Associated Virus Vector-Based Gene Therapy Market
14 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Dynamics
15 Supplier Landscape
16 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Distribution Model (Additional Insight)
17 Payment Methods (Additional Insight)
Companies Mentioned
- Arya Sciences Acquisition Corp.
- Pfizer Inc.
- Roche Holding AG
- BioMarin Pharmaceutical Inc.
- Bayer AG
- Coave Therapeutics
- MeiraGTx Limited
- Neurocrine Biosciences, Inc.
- Biogen, Inc.
- Sangamo Therapeutics
- Sarepta Therapeutics, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 147 |
| Published | April 2023 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 0.95 Billion |
| Forecasted Market Value ( USD | $ 3.69 Billion |
| Compound Annual Growth Rate | 18.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
Related Reports
Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Pipeline Insight, 2024
- Drug Pipelines
- 280 Pages
- Global
From
From
Gene Therapy Market Report by Gene Type, Vector Type, Delivery Method, Application, and Region 2024-2032
- Report
- 136 Pages
- Global
From
Gene Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030
- Report
- 150 Pages
- Global
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
